Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Dose-Finding Study and Pharmacokinetics Profile of the Novel 13-Mer Antisense miR-221 Inhibitor in Sprague-Dawley Rats.

Di Martino MT, Arbitrio M, Caracciolo D, Scionti F, Tagliaferri P, Tassone P.

Mol Ther Nucleic Acids. 2020 Feb 8;20:73-85. doi: 10.1016/j.omtn.2020.01.036. [Epub ahead of print]

2.

Influence of the Fabrication Accuracy of Hot-Embossed PCL Scaffolds on Cell Growths.

Limongi T, Dattola E, Botta C, Coluccio ML, Candeloro P, Cucè M, Scopacasa B, Gallo Cantafio ME, Critello CD, Pullano SA, Fiorillo AS, Tagliaferri P, Tassone P, Lamanna E, Di Fabrizio E, Perozziello G.

Front Bioeng Biotechnol. 2020 Feb 14;8:84. doi: 10.3389/fbioe.2020.00084. eCollection 2020.

3.

Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma.

Caracciolo D, Scionti F, Juli G, Altomare E, Golino G, Todoerti K, Grillone K, Riillo C, Arbitrio M, Iannone M, Morelli E, Amodio N, Di Martino MT, Rossi M, Neri A, Tagliaferri P, Tassone P.

Haematologica. 2020 Feb 20. pii: haematol.2019.240713. doi: 10.3324/haematol.2019.240713. [Epub ahead of print]

4.

The Non-Coding RNA Landscape of Plasma Cell Dyscrasias.

Morelli E, Gullà A, Rocca R, Federico C, Raimondi L, Malvestiti S, Agosti V, Rossi M, Costa G, Giavaresi G, Azab KA, Cagnetta A, Cea M, Tagliaferri P, Neri A, Munshi NC, Viglietto G, Tassone P, Amodio N.

Cancers (Basel). 2020 Jan 30;12(2). pii: E320. doi: 10.3390/cancers12020320. Review.

5.

Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.

Nardone V, Tini P, Pastina P, Botta C, Reginelli A, Carbone SF, Giannicola R, Calabrese G, Tebala C, Guida C, Giudice A, Barbieri V, Tassone P, Tagliaferri P, Cappabianca S, Capasso R, Luce A, Caraglia M, Mazzei MA, Pirtoli L, Correale P.

Oncol Lett. 2020 Feb;19(2):1559-1566. doi: 10.3892/ol.2019.11220. Epub 2019 Dec 16.

6.

Could PD-1/PDL1 immune checkpoints be linked to HLA signature?

Correale P, Saladino RE, Nardone V, Giannicola R, Agostino R, Pirtoli L, Caraglia M, Botta C, Tagliaferri P.

Immunotherapy. 2019 Dec;11(18):1523-1526. doi: 10.2217/imt-2019-0160. Epub 2019 Dec 9. No abstract available.

7.

Allometric Scaling Approaches for Predicting Human Pharmacokinetic of a Locked Nucleic Acid Oligonucleotide Targeting Cancer-Associated miR-221.

Di Martino MT, Arbitrio M, Fonsi M, Erratico CA, Scionti F, Caracciolo D, Tagliaferri P, Tassone P.

Cancers (Basel). 2019 Dec 19;12(1). pii: E27. doi: 10.3390/cancers12010027.

8.

GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up.

Caraglia M, Correale P, Giannicola R, Staropoli N, Botta C, Pastina P, Nesci A, Caporlingua N, Francini E, Ridolfi L, Mini E, Roviello G, Ciliberto D, Agostino RM, Strangio A, Azzarello D, Nardone V, Falzea A, Cappabianca S, Bocchetti M, D'Arrigo G, Tripepi G, Tassone P, Addeo R, Giordano A, Pirtoli L, Francini G, Tagliaferri P.

Front Oncol. 2019 Nov 8;9:1102. doi: 10.3389/fonc.2019.01102. eCollection 2019.

9.

Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.

Lorusso D, Ferrandina G, Colombo N, Pignata S, Pietragalla A, Sonetto C, Pisano C, Lapresa MT, Savarese A, Tagliaferri P, Lombardi D, Cinieri S, Breda E, Sabatucci I, Sabbatini R, Conte C, Cecere SC, Maltese G, Scambia G.

Gynecol Oncol. 2019 Dec;155(3):406-412. doi: 10.1016/j.ygyno.2019.10.013. Epub 2019 Oct 31.

PMID:
31677820
10.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

11.

A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.

Catalano R, Rocca R, Juli G, Costa G, Maruca A, Artese A, Caracciolo D, Tagliaferri P, Alcaro S, Tassone P, Amodio N.

Eur J Med Chem. 2019 Dec 1;183:111715. doi: 10.1016/j.ejmech.2019.111715. Epub 2019 Sep 17.

PMID:
31550663
12.

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis.

Galvano A, Taverna S, Badalamenti G, Incorvaia L, Castiglia M, Barraco N, Passiglia F, Fulfaro F, Beretta G, Duro G, Vincenzi B, Tagliaferri P, Bazan V, Russo A.

Ther Adv Med Oncol. 2019 Sep 10;11:1758835919874653. doi: 10.1177/1758835919874653. eCollection 2019.

13.

Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma.

Juli G, Oliverio M, Bellizzi D, Gallo Cantafio ME, Grillone K, Passarino G, Colica C, Nardi M, Rossi M, Procopio A, Tagliaferri P, Tassone P, Amodio N.

Cancers (Basel). 2019 Jul 16;11(7). pii: E990. doi: 10.3390/cancers11070990.

14.

Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.

Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, Tassone P, Tagliaferri P, Correale P.

Mol Clin Oncol. 2019 Jul;11(1):81-90. doi: 10.3892/mco.2019.1859. Epub 2019 May 16.

15.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.

16.

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma.

Misso G, Zarone MR, Lombardi A, Grimaldi A, Cossu AM, Ferri C, Russo M, Vuoso DC, Luce A, Kawasaki H, Di Martino MT, Virgilio A, Festa A, Galeone A, De Rosa G, Irace C, Donadelli M, Necas A, Amler E, Tagliaferri P, Tassone P, Caraglia M.

Mol Ther Nucleic Acids. 2019 Jun 7;16:391-406. doi: 10.1016/j.omtn.2019.02.023. Epub 2019 Mar 13.

17.

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

Pignata S, Scambia G, Lorusso D, De Giorgi U, Nicoletto MO, Lauria R, Mosconi AM, Sacco C, Omarini C, Tagliaferri P, Ferrandina G, Cinieri S, Savarese A, Valabrega G, Pisano C, Salutari V, Raspagliesi F, Kopf B, Cecere SC, Amadio G, Maltese G, Di Napoli M, Greggi S, Signoriello S, Daniele G, Sacco A, Losito S, Normanno N, Perrone F, Gallo C, Piccirillo MC; MITO Investigators.

Gynecol Oncol. 2019 Jun;153(3):535-540. doi: 10.1016/j.ygyno.2019.03.260. Epub 2019 Apr 9.

PMID:
30979589
18.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.

Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C.

J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.

19.

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P.

Cancers (Basel). 2019 Feb 18;11(2). pii: E236. doi: 10.3390/cancers11020236.

20.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.

Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P.

Clin Pharmacol Ther. 2019 Aug;106(2):422-431. doi: 10.1002/cpt.1391. Epub 2019 Mar 28.

PMID:
30739312
21.

How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies.

Nardone V, Pastina P, Giannicola R, Agostino R, Croci S, Tini P, Pirtoli L, Giordano A, Tagliaferri P, Correale P.

Front Immunol. 2018 Dec 12;9:2941. doi: 10.3389/fimmu.2018.02941. eCollection 2018. No abstract available.

22.

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives.

Arbitrio M, Di Martino MT, Scionti F, Barbieri V, Pensabene L, Tagliaferri P.

High Throughput. 2018 Dec 18;7(4). pii: E40. doi: 10.3390/ht7040040. Review.

23.

The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.

Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, Salvino A, Barbieri V, Russo A, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 Nov;131:83-89. doi: 10.1016/j.critrevonc.2018.08.011. Epub 2018 Sep 3. Review.

PMID:
30293710
24.

The potential role of miRNAs in multiple myeloma therapy.

Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P.

Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Review.

PMID:
30148649
25.

miR-22 suppresses DNA ligase III addiction in multiple myeloma.

Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P.

Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17.

26.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11.

27.

Impact of Natural Dietary Agents on Multiple Myeloma Prevention and Treatment: Molecular Insights and Potential for Clinical Translation.

Raimondi L, De Luca A, Giavaresi G, Barone A, Tagliaferri P, Tassone P, Amodio N.

Curr Med Chem. 2020;27(2):187-215. doi: 10.2174/0929867325666180629153141.

PMID:
29956610
28.

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.

Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P.

Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17.

29.

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.

Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P.

J Hematol Oncol. 2018 May 8;11(1):63. doi: 10.1186/s13045-018-0606-4. Review.

30.

Mouse models of multiple myeloma: technologic platforms and perspectives.

Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P.

Oncotarget. 2018 Apr 13;9(28):20119-20133. doi: 10.18632/oncotarget.24614. eCollection 2018 Apr 13. Review.

31.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.

Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, Vivacqua A.

J Exp Clin Cancer Res. 2018 May 2;37(1):94. doi: 10.1186/s13046-018-0767-6.

32.

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.

Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, Botta C, Arbitrio M, Correale P, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 May;125:69-77. doi: 10.1016/j.critrevonc.2018.03.003. Epub 2018 Mar 9. Review.

PMID:
29650279
33.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.

Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Sep;32(9):1948-1957. doi: 10.1038/s41375-018-0067-3. Epub 2018 Feb 22.

34.

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients.

Botta C, Ciliberto D, Rossi M, Staropoli N, Cucè M, Galeano T, Tagliaferri P, Tassone P.

Blood Adv. 2017 Feb 27;1(7):455-466. doi: 10.1182/bloodadvances.2016003905. eCollection 2017 Feb 28.

35.

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.

Stamato MA, Juli G, Romeo E, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, Tassone P, Amodio N.

Oncotarget. 2017 Nov 20;8(63):106527-106537. doi: 10.18632/oncotarget.22507. eCollection 2017 Dec 5.

36.

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

Zarone MR, Misso G, Grimaldi A, Zappavigna S, Russo M, Amler E, Di Martino MT, Amodio N, Tagliaferri P, Tassone P, Caraglia M.

Sci Rep. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.

37.

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P.

J Thorac Dis. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68.

38.

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.

Gullà A, Hideshima T, Bianchi G, Fulciniti M, Kemal Samur M, Qi J, Tai YT, Harada T, Morelli E, Amodio N, Carrasco R, Tagliaferri P, Munshi NC, Tassone P, Anderson KC.

Leukemia. 2018 Apr;32(4):996-1002. doi: 10.1038/leu.2017.334. Epub 2017 Nov 21.

39.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.

Botta C, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Apr;32(4):1003-1015. doi: 10.1038/leu.2017.336. Epub 2017 Nov 21.

40.

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P.

Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29.

41.

Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study.

de Castro J, Tagliaferri P, de Lima VCC, Ng S, Thomas M, Arunachalam A, Cao X, Kothari S, Burke T, Myeong H, Grattan A, Lee DH.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12734. Epub 2017 Jul 27.

42.

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

Botta C, Cuce M, Caracciolo D, Fiorillo L, Tagliaferri P, Tassone P.

Curr Cancer Drug Targets. 2017;17(9):819-838. doi: 10.2174/1568009617666170330154756. Review.

PMID:
28359248
43.

Immunotherapy of colorectal cancer: new perspectives after a long path.

Correale P, Botta C, Ciliberto D, Pastina P, Ingargiola R, Zappavigna S, Tassone P, Pirtoli L, Caraglia M, Tagliaferri P.

Immunotherapy. 2016 Nov;8(11):1281-1292. Review.

PMID:
27993089
44.

A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival.

Botta C, Di Martino MT, Ciliberto D, Cucè M, Correale P, Rossi M, Tagliaferri P, Tassone P.

Blood Cancer J. 2016 Dec 16;6(12):e511. doi: 10.1038/bcj.2016.118.

45.

Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.

Nardone V, Botta C, Caraglia M, Martino EC, Ambrosio MR, Carfagno T, Tini P, Semeraro L, Misso G, Grimaldi A, Boccellino M, Facchini G, Berretta M, Vischi G, Rocca BJ, Barone A, Tassone P, Tagliaferri P, Del Vecchio MT, Pirtoli L, Correale P.

Cancer Biol Ther. 2016 Nov;17(11):1213-1220.

46.

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation.

Staropoli N, Ciliberto D, Chiellino S, Caglioti F, Giudice TD, Gualtieri S, Salvino A, Strangio A, Botta C, Pignata S, Tassone P, Tagliaferri P.

Oncotarget. 2016 Dec 13;7(50):82741-82756. doi: 10.18632/oncotarget.12633. Review.

47.

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P.

Cell Death Discov. 2016 Oct 3;2:16025. eCollection 2016.

48.

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.

Agapito G, Botta C, Guzzi PH, Arbitrio M, Di Martino MT, Tassone P, Tagliaferri P, Cannataro M.

Microarrays (Basel). 2016 Sep 23;5(4). pii: E24. doi: 10.3390/microarrays5040024.

49.

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.

Botta C, Misso G, Martino EC, Pirtoli L, Cusi MG, Tassone P, Tagliaferri P, Caraglia M, Correale P.

Cell Death Dis. 2016 Jul 21;7:e2299. doi: 10.1038/cddis.2016.211. No abstract available.

50.

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.

Gallo Cantafio ME, Nielsen BS, Mignogna C, Arbitrio M, Botta C, Frandsen NM, Rolfo C, Tagliaferri P, Tassone P, Di Martino MT.

Mol Ther Nucleic Acids. 2016 Jun 21;5(6). doi: 10.1038/mtna.2016.36. Erratum in: Mol Ther Nucleic Acids. 2016 Jul 19;5(7):e336.

Supplemental Content

Loading ...
Support Center